Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Meghan D. Jones's research has explored several areas within health sciences. Her work includes a retrospective review of musculoskeletal care within a military health system and an examination of the duration of lymphopenia after CAR-T cell therapy and its association with non-melanoma skin cancers and survival rates. Jones also investigated early administration of bispecific antibodies following CAR-T infusion for specific lymphoma types. Her earlier research involved the synthesis and in vitro evaluation of disquaramide compounds as potential anti-leishmanial drugs. Jones has collaborated with researchers from the University of Arkansas for Medical Sciences and the University of Central Arkansas.
Metrics
- Publications: 3
Selected Publications
-
Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs (2024)
-
Comparing Administration of Nutrition Support With Prescribed Dose (2011)
Collaboration Network
Top Collaborators
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
- Synthesis and in vitro evaluation shows disquaramide compounds are a promising class of anti-leishmanial drugs
Similar Researchers
Based on overlapping research topics